I was just playing devil's advocate, thanks for the update/history lesson.
just curious though, why did Icahn invest not once but twice in this petri dish of a company?
where did he think he was going to wring out any value?
known it all along, not quite sure how they carry it out or get on the same page but they sure as hell are experts at it.
well hotman, it didn't quite get there today but it was still a nice move.
coming into today i was bullish on googl thinkin amzn would lift it up and that it could get back over $700 but there was something in your conviction that made me take a second look.
I had 10 695 calls @ .40 (bought near close yesterday) going into today which ended up zero for a small loss $400ish
I couldnt quite get all-in on your $600 target given that the last time googl shot up for earnings it never filled that gap. I know there was a lot of air to fill but 650 is a major psych level. I did take a look at the put strikes this morning and settled on the 670s, picked up 10 @ 3.30ish
I also took a stab at your hypothesis of a collapse and bought 50 650s @ .25 just in case it did fall apart. Got close to that psych level (653) but that was all she had in the tank. I was able to get rid of them for the same .25 so a wash except commissions.
Scored on the 670's sold them $14 ish
Not a bad day and thanks for your thoughts hotman, it caused me to re-evaluate.
Hope some of you were able to do the same.
eom, funds taking profits?
you don't get handed billions in gains and not ring the register
so just to kick the can a bit...
Since he took a stake in NFLX and singlehandedly forced BB into BK didn't that essentially wipe out the competition and pave the way for NFLX to dominate?
The result... a stake he recently sold for billions
crazy like a fox?
Well yes, the actual date for Edwards SAPIEN 3 was in June but it was announced by the FDA on 7/20. Here is the email...
From: U.S. Food & Drug Administration (FDA)
Sent: Monday, July 20, 2015 6:13 AM
Subject: Recent Device Approvals: Edwards SAPIEN 3 Transcatheter Heart Valve
This is why when people were speculating FDA this and FDA that, I said we would be hearing from the company before we received official word from the FDA
I'd say there is zero chance we hear from the FDA in July re: the INVOcell.
Seems like a real newbie question, surprised that you found your way here but no matter.
Typically the acquiring company will make an offer, let's say $5 per share. On announcement the shares will more than likely go up near that price (ie. $4.75 or so) so you can sell close to the offer or wait until the deal is completed, could take months depending on the complexity.
Another thing that could happen is that the stock starts to trade higher because the market could view the offer as too low and there could be speculation of another bidder making an offer. This is the case w/ CELG bidding for RCPT, many think someone else will enter w/ a bid but I don't thnk that will happen here. w IVOB
And yes, you are forced to sell, you dont have an option to opt out unless the sale is blocked by a majority of shareholders.
activL® Artificial Disc
The FDA recently approved the activL® Artificial Disc to be marketed. The activL® Artificial Disc is an implant that replaces the function of a damaged or diseased spinal disc. The activL® consists of two metal (cobalt-chromium with a titanium coating) endplates surrounding a plastic (polyethylene) insert. The endplates attach to the patient’s vertebrae, and the plastic insert fits between them. The insert is designed to move during daily activities.
Edwards SAPIEN 3 Transcatheter Heart Valve
The FDA has recently approved the Edwards SAPIEN 3 Transcatheter Heart Valve to be marketed. The Edwards SAPIEN 3 Transcatheter Heart Valve (often referred to as SAPIEN 3 THV) consists of a catheter-based artificial aortic heart valve and accessories used to implant the valve without open-heart surgery. The valve is made of cow tissue attached to a balloon-expandable, cobalt-chromium frame for support. The SAPIEN 3 THV is the third generation of the SAPIEN THV that FDA originally approved in 2011. The device has a major design change that adds a skirt at the base of the valve frame to minimize leakage around the valve.
VENTANA ALK (D5F3) CDx Assay
The FDA has recently approved the VENTANA ALK (D5F3) CDx Assay to be marketed. This is a laboratory immunohistochemical (IHC) test that identifies whether the anaplastic lymphoma kinase (ALK) protein is present in a non-small cell lung cancer (NSCLC) tissue sample. If the test result indicates that the ALK protein is present, then the patient with NSCLC may be eligible for treatment with the cancer drug Xalkori® (crizotinib).
Xalkori is a drug used to treat patients with advanced (locally or metastatic) NSCLC who have ALK positive tumors. Xalkori selectively interferes with the ALK protein and stops cancer cell growth in NSCLC.
PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire), and Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire)
The FDA has recently approved the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire) and the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire) to be marketed. The PROMUS Element Plus and Promus PREMIER stent systems each consists of two components: the stent and the catheter delivery system. The PROMUS Element Plus and Promus PREMIER stents are metal tubes with the drug everolimus contained in a thin coating on the stent’s surface.
The PROMUS Element Plus and Promus PREMIER stents are mounted on a folded balloon attached to a catheter delivery system and placed into a blood vessel (coronary artery)supplying blood to the heart. The stent helps to keep the coronary artery open and it is made of a platinum-chromium metal alloy.
The PROMUS Element Plus stent uses the identical drug coating formulation and drug dose density as the approved PROMUS/XIENCE V stent. The PROMUS Element Plus uses the identical stent materials, stent design, and balloon materials as the approved ION stent. The Promus PREMIER System is very similar to the PROMUS Element Plus stent, but has additional metal connector wires in its structure. Due to the extra connectors on the stent there is a very slight increase in the amount of drug on the Promus PREMIER stent.
Not an article, rather a market research report which costs about $2,500 or so.